Fundz

BioMarin to acquire Alesta Therapeutics for $275 million

PUBLIC · BMRNAug 18, 2026

Acquiring Company

BioMarin Pharmaceutical

Acquired Company

Alesta Therapeutics

San RafaelBiotechnologyHealth CareMedicalGeneticsTherapeuticsBiotechnologyHealth CareTherapeutics

Description

BioMarin Pharmaceutical Inc. has announced its agreement to acquire Alesta Therapeutics for $275 million upfront, with additional payments based on milestones. This acquisition aims to bring Alesta's promising product, ALE1, to market as a potential first oral therapy for hypophosphatasia. The transaction is expected to close this quarter, following customary conditions.

Who to call at BioMarin Pharmaceutical, and when

When BioMarin Pharmaceutical changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day BioMarin Pharmaceutical raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at BioMarin Pharmaceutical, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at BioMarin Pharmaceutical. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

BioMarin Pharmaceutical

Location

San Rafael, California, United States

About

BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of genetic conditions.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment BioMarin Pharmaceutical makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Claudia
Senior decision-maker at this company
••••••••@••••••••

See Claudia's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for BioMarin Pharmaceutical's next move

Learn about Strategic plan

Frequently asked

Who acquired Alesta Therapeutics?

Alesta Therapeutics was acquired by BioMarin Pharmaceutical, based in San Rafael. The deal was reported on August 18, 2026. BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery. BioMarin Pharmaceutical is publicly traded (BMRN) and operates in Biotechnology.

When did BioMarin Pharmaceutical acquire Alesta Therapeutics?

BioMarin Pharmaceutical's acquisition of Alesta Therapeutics was reported on August 18, 2026. BioMarin Pharmaceutical Inc. has announced its agreement to acquire Alesta Therapeutics for $275 million upfront, with additional payments based on milestones. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Alesta Therapeutics do?

Alesta Therapeutics is a biotechnology company focused on developing therapies for rare genetic diseases. The company is engaged in advancing innovative treatments and conducting clinical trials to find effective solutions for serious health conditions. It is privately held, operating in Biotechnology.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.